Nasus Pharma Ltd. Ordinary Shares (NSRX)
NSRX moved a median of 0.00% 30 minutes after news, and +0.19% by the close. How NSRX actually reacts to news — the realized, point-in-time move the market made, measured across 87 labeled events over the last three years with zero look-ahead.
NSRX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 34% | 62 |
| 30-min | 0.00% | 46% | 68 |
| 60-min | 0.00% | 49% | 71 |
| to close | +0.19% | 50% | 78 |
| Middle 50% of NSRX reactions | -2.78% to +1.37% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 87 |
Half of all Nasus Pharma Ltd. Ordinary Shares news events land between -2.78% and +1.37% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when NSRX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to NSRX's baseline. Nothing else.
Recent NSRX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 6-K Nasus Pharma Ltd For: Oct 08 | SEC filing · Form 6-K | SEC EDGAR | — | -3.31% | |
| Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron | Press release | GlobeNewswire | -2.39% | -5.05% | |
| Form 6-K Nasus Pharma Ltd For: Sep 18 | SEC filing · Form 6-K | SEC EDGAR | — | -0.58% | |
| Form 6-K Nasus Pharma Ltd For: Sep 14 | SEC filing · Form 6-K | SEC EDGAR | -3.20% | +8.31% | |
| Form EFFECT Nasus Pharma Ltd | SEC filing · Form EFFECT | SEC EDGAR | -3.20% | +8.31% | |
| Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis | Press release | GlobeNewswire | -3.20% | +8.31% | |
| Nasus Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference | Press release | GlobeNewswire | — | +4.02% | |
| Form 6-K Nasus Pharma Ltd For: Sep 04 | SEC filing · Form 6-K | SEC EDGAR | — | +4.02% | |
| Form F-3 Nasus Pharma Ltd | SEC filing · Form F-3 | SEC EDGAR | — | +1.07% | |
| Form EFFECT Nasus Pharma Ltd | SEC filing · Form EFFECT | SEC EDGAR | — | +5.26% | |
| Form 6-K Nasus Pharma Ltd For: Aug 19 | SEC filing · Form 6-K | SEC EDGAR | +9.99% | +21.91% | |
| Form POS AM Nasus Pharma Ltd | SEC filing · Form POS | SEC EDGAR | +9.99% | +21.91% | |
| Nasus Pharma Announces Transition of Chief Financial Officer | Press release | GlobeNewswire | +9.99% | +21.91% | |
| Form 6-K Nasus Pharma Ltd For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +0.00% | |
| Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Form 6-K Nasus Pharma Ltd For: Jul 28 | SEC filing · Form 6-K | SEC EDGAR | +0.56% | +2.37% | |
| Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growth | Press release | GlobeNewswire | +0.56% | +2.37% | |
| Nasus Pharma to Participate in the Zacks Life Sciences Investor Forum | Press release | GlobeNewswire | +0.00% | +0.65% | |
| Form 6-K Nasus Pharma Ltd For: Jun 09 | SEC filing · Form 6-K | SEC EDGAR | +6.83% | +8.99% | |
| Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003) | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Nasus Pharma to Host Virtual KOL Event on June 10, 2026 to Discuss NS002 for the Treatment of Anaphylaxis | Press release | GlobeNewswire | +0.32% | -5.11% | |
| Form S-8 Nasus Pharma Ltd | SEC filing · Form S-8 | SEC EDGAR | -0.17% | +4.50% | |
| Nasus Pharma to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.00% | -1.43% | |
| Form EFFECT Nasus Pharma Ltd | SEC filing · Form EFFECT | SEC EDGAR | +1.32% | +11.84% | |
| Form POS AM Nasus Pharma Ltd | SEC filing · Form POS | SEC EDGAR | -0.90% | -9.46% | |
| Form 20-F Nasus Pharma Ltd For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | +1.96% | +8.23% | |
| Form 6-K Nasus Pharma Ltd For: Mar 25 | SEC filing · Form 6-K | SEC EDGAR | +3.56% | -5.14% | |
| Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update | Press release | GlobeNewswire | +1.96% | +8.23% | |
| Form 6-K Nasus Pharma Ltd For: Mar 16 | SEC filing · Form 6-K | SEC EDGAR | -5.67% | -18.21% | |
| Form EFFECT Nasus Pharma Ltd | SEC filing · Form EFFECT | SEC EDGAR | -5.67% | -18.21% | |
| Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen® with Accelerated Speed to Therapeutic Threshold | Press release | GlobeNewswire | -5.67% | -18.21% | |
| Nasus Pharma to Present and Participate in the Upcoming Life Sciences Investor Forum | Press release | GlobeNewswire | — | -9.67% | |
| Nasus Pharma to Present Topline Analysis from NS002 Intranasal Epinephrine Powder Phase 2 Single and Repeat Dose Clinical Study | Press release | GlobeNewswire | — | -9.67% | |
| Form 6-K Nasus Pharma Ltd For: Mar 06 | SEC filing · Form 6-K | SEC EDGAR | — | -9.67% | |
| Form 6-K Nasus Pharma Ltd For: Mar 04 | SEC filing · Form 6-K | SEC EDGAR | — | +0.00% | |
| Form F-1 Nasus Pharma Ltd | SEC filing · Form F-1 | SEC EDGAR | — | +5.32% | |
| Form D Nasus Pharma Ltd | SEC filing · Form D | SEC EDGAR | — | -7.27% | |
| Form 6-K Nasus Pharma Ltd For: Feb 23 | SEC filing · Form 6-K | SEC EDGAR | — | +2.94% | |
| Nasus Pharma to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.00% | +18.00% | |
| Nasus Pharma to Present Data Highlighting Superior Nasal Deposition and Stability of Intranasal Epinephrine Powder at AAAAI 2026 | Press release | GlobeNewswire | +0.00% | -7.88% | |
| Form 6-K Nasus Pharma Ltd For: Feb 13 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +7.08% | |
| Nasus Pharma Announces Closing of $15.0 Million Private Placement | Press release | GlobeNewswire | +0.00% | +7.08% | |
| Form 6-K Nasus Pharma Ltd For: Feb 11 | SEC filing · Form 6-K | SEC EDGAR | — | — | |
| Nasus Pharma Announces Pricing of $15.0 Million Private Placement | Press release | GlobeNewswire | — | +14.05% | |
| Form 6-K Nasus Pharma Ltd For: Jan 29 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +2.32% | |
| Form 6-K Nasus Pharma Ltd For: Jan 20 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -6.86% | |
| Nasus Pharma Announces Positive Interim Results from Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder | Press release | GlobeNewswire | +0.00% | -6.86% | |
| Form 6-K Nasus Pharma Ltd For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | — | -1.32% | |
| Form 6-K Nasus Pharma Ltd For: Dec 22 | SEC filing · Form 6-K | SEC EDGAR | -8.23% | -10.40% | |
| Nasus Pharma CEO Issues 2025 Letter to Shareholders | Press release | GlobeNewswire | -8.23% | -10.40% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the NSRX section they belong to.
Where else NSRX is measured.
NSRX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Nasus Pharma Ltd. Ordinary Shares's median reaction calculated?
Every labeled NSRX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 87 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 46% of NSRX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does NSRX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.